Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.40 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | G6PD | P11413 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2365365 | 0.99 | HPGD (0.43) | HPGDALDH1A1CNR2MEN1KMT2A | |
| SCHEMBL12608696 | 0.96 | HPGD (0.44) | HPGDALDH1A1CNR2MEN1KMT2A | |
| SCHEMBL14548898 | 0.92 | SIGMAR1 (0.39) | HPGDALDH1A1CNR2MEN1KMT2A | |
| SCHEMBL12608676 | 0.90 | HPGD (0.49) | HPGDALDH1A1CNR2MEN1KMT2A | |
| SCHEMBL12608677 | 0.85 | HPGD (0.47) | HPGDALDH1A1CNR2MEN1KMT2A | |
| SCHEMBL15848965 | 0.84 | HPGD (0.58) | HPGDALDH1A1CNR2KDM4EHTT | |
| SCHEMBL15848967 | 0.83 | CNR2 (0.46) | HPGDALDH1A1CNR2SIGMAR1 | |
| SCHEMBL12608637 | 0.81 | CNR2 (0.51) | HPGDALDH1A1CNR2MEN1KMT2A | |
| SCHEMBL16548465 | 0.81 | KDM4E (0.53) | HPGDALDH1A1CNR2MEN1KMT2A | |
| SCHEMBL13418993 | 0.81 | CNR2 (0.55) | HPGDALDH1A1CNR2KMT2ARAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190082845-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-10137109-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| US-20170165229-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON, INC. | 2017-06-15 | — | — | US | disclosed |
| US-9566265-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (US) | 2017-02-14 | — | — | US | disclosed |
| US-20150342927-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON, INC. | 2015-12-03 | — | — | US | disclosed |
| US-9108916-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (US) | 2015-08-18 | — | — | US | disclosed |
| CN-102203063-B | Carbazole compounds and therapeutic uses of the compounds | INCURON LLC | 2014-11-26 | — | — | CN | disclosed |
| US-20140303224-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON, LLC (US) | 2014-10-09 | — | — | US | disclosed |
| US-8765738-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2356093-B1 | Carbazole compounds and therapeutic uses of the compounds | INCURON LLC (RU) | 2013-01-09 | — | — | EP | disclosed |
| US-20110305661-A1 | Carbazole Compounds and Therapeutic Uses of the Compounds | INCURON, INC. | 2011-12-15 | — | — | US | disclosed |
| EP-2356093-A1 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (RU) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010042445-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | CLEVELAND BIOLABS, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165229-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | MALT1, PAICS, BCL9 | SIGMAR1 3981/4885EGFR 2958/4885HPGD 212/4885 |
| US-20150342927-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | MALT1, PAICS, BCL9 | SIGMAR1 3981/4885EGFR 2958/4885HPGD 212/4885 |
| US-10137109-B2 | Carbazole compounds and therapeutic uses of the compounds | MALT1, PAICS, BCL9 | SIGMAR1 3981/4885EGFR 2958/4885HPGD 212/4885 |
| US-20110305661-A1 | Carbazole Compounds and Therapeutic Uses of the Compounds | MALT1, PAICS, TPMT | SIGMAR1 3959/4885EGFR 2791/4885HPGD 208/4885 |
| US-20140303224-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | MALT1, PAICS, BCL9 | SIGMAR1 3981/4885EGFR 2958/4885HPGD 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.